One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
“Biomarker analyses from randomized trials in clear cell renal cell carcinoma�
Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials☆
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)☆
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy
European cancer mortality predictions for the year 2025 with focus on breast cancer
Comments on the study of correlation between progression-free and overall survival in patients with Hodgkin lymphoma
Reply to the Letter to the Editor ‘Comments on the study of correlation between progression-free and overall survival in patients with Hodgkin lymphoma’ by Zeng et al.
Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group�: [Ann Oncol 35 (2024) 588-606]
Corrigendum to “582P Knowledge, attitude and practices of physicians in Pakistan towards onco-hypertension�: [Annals of Oncology 35 (2024) S1612]
